JP2017516784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516784A5 JP2017516784A5 JP2016569606A JP2016569606A JP2017516784A5 JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5 JP 2016569606 A JP2016569606 A JP 2016569606A JP 2016569606 A JP2016569606 A JP 2016569606A JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003798P | 2014-05-28 | 2014-05-28 | |
| US62/003,798 | 2014-05-28 | ||
| US201462088200P | 2014-12-05 | 2014-12-05 | |
| US62/088,200 | 2014-12-05 | ||
| PCT/US2015/032990 WO2015184145A1 (en) | 2014-05-28 | 2015-05-28 | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516784A JP2017516784A (ja) | 2017-06-22 |
| JP2017516784A5 true JP2017516784A5 (OSRAM) | 2018-07-05 |
| JP6648040B2 JP6648040B2 (ja) | 2020-02-14 |
Family
ID=54699806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569606A Active JP6648040B2 (ja) | 2014-05-28 | 2015-05-28 | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10238630B2 (OSRAM) |
| EP (1) | EP3148336B1 (OSRAM) |
| JP (1) | JP6648040B2 (OSRAM) |
| WO (1) | WO2015184145A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7982060B2 (en) | 2004-06-03 | 2011-07-19 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
| MY160203A (en) | 2009-03-30 | 2017-02-28 | Eisai R&D Man Co Ltd | Liposome composition |
| KR102265952B1 (ko) | 2013-06-26 | 2021-06-16 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 |
| ITUB20159206A1 (it) * | 2015-12-22 | 2017-06-22 | Olon Spa | Forme cristalline e amorfe di olaparib |
| JP7015237B2 (ja) | 2016-04-28 | 2022-02-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
| DK3478286T3 (da) * | 2016-06-29 | 2024-01-29 | Tesaro Inc | Fremgangsmåder til behandling af ovariecancer |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| CA3052330A1 (en) * | 2017-02-06 | 2018-08-09 | City Of Hope | Treatment of cancer |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) * | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN107098862A (zh) * | 2017-06-05 | 2017-08-29 | 山东裕欣药业有限公司 | 一种奥拉帕尼二水合物及其制备方法 |
| BR112020006039A2 (pt) * | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| SG11202002862RA (en) | 2017-09-30 | 2020-04-29 | Tesaro Inc | Combination therapies for treating cancer |
| KR20200067164A (ko) | 2017-10-06 | 2020-06-11 | 테사로, 인코포레이티드 | 조합 요법 및 그의 용도 |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20210030735A1 (en) * | 2018-02-05 | 2021-02-04 | Tesaro, Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| EP4552696A3 (en) * | 2018-05-15 | 2025-11-05 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| JP2022516170A (ja) * | 2019-01-04 | 2022-02-24 | アクティニウム ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| EP4319729A4 (en) * | 2021-04-09 | 2025-02-26 | Cardiff Oncology, Inc. | CANCER TREATMENT WITH PARP INHIBITORS AND PLK1 INHIBITORS |
| WO2022216908A1 (en) | 2021-04-09 | 2022-10-13 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| WO2024054898A1 (en) * | 2022-09-08 | 2024-03-14 | Cardiff Oncology, Inc. | Onvansertib and parp inhibitor combination |
| KR20250102017A (ko) | 2022-09-11 | 2025-07-04 | 카디프 온콜로지, 인크. | 전이성 암 치료용 항혈관형성제와 병용되는 plk1 억제제 |
| WO2024137738A1 (en) * | 2022-12-22 | 2024-06-27 | The Board Of Regents Of The University Of Oklahoma | Combinations of poly (adp-ribose) polymerase (parp) inhibitors and heteroarotinoids and methods of use as cancer treatments |
| CN121127241A (zh) * | 2023-03-10 | 2025-12-12 | 万春药业公司 | 肿瘤联合治疗及使用方法 |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| SI2209375T1 (sl) * | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| SG193489A1 (en) | 2011-03-18 | 2013-10-30 | Eisai R&D Man Co Ltd | Methods and compositions for predicting response to eribulin |
| MX359664B (es) * | 2011-07-29 | 2018-10-05 | Univ Colorado Regents | Tratamiento de cáncer de mama. |
-
2015
- 2015-05-28 WO PCT/US2015/032990 patent/WO2015184145A1/en not_active Ceased
- 2015-05-28 JP JP2016569606A patent/JP6648040B2/ja active Active
- 2015-05-28 US US15/314,200 patent/US10238630B2/en active Active
- 2015-05-28 EP EP15799685.1A patent/EP3148336B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516784A5 (OSRAM) | ||
| EP3148336B1 (en) | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| TWI361689B (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| Rajawat et al. | Therapeutic targeting of poly (ADP‐ribose) polymerase‐1 (PARP1) in cancer: Current developments, therapeutic strategies, and future opportunities | |
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| TW200932239A (en) | PARP inhibitor compounds, compositions and methods of use | |
| JP2020516693A5 (OSRAM) | ||
| EP3969050A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| CN103458896A (zh) | 用于治疗癌症的方法 | |
| AU2017205749B2 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| KR20180129917A (ko) | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 | |
| Ali et al. | Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers | |
| JP2013511526A5 (OSRAM) | ||
| CN101484443A (zh) | 放射线治疗增强剂 | |
| Goldman et al. | MA07. 05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC) | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| Han et al. | Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells | |
| CN102105147B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| Cao et al. | Poly (ADP-Ribosyl) polymerase 1 inhibitors: A patent review | |
| CN111777621B (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| TW202508573A (zh) | 用於治療癌症之組合療法 | |
| WO2025212165A1 (en) | Targeted heterobifunctional small molecule proteolysis targeting chimeras | |
| TWI307628B (en) | Use of zd0473 in combination with a non-platinum based anti-cancer agent |